ProPhase Labs Secures Patent for Esophageal Cancer Risk Detection
ProPhase Labs, Inc. has achieved a significant milestone with the issuance of U.S. Patent No. 12379378-B2. This patent focuses on innovative biomarker-driven systems and methods designed to assess the risk progression in Barrett’s esophagus and esophageal adenocarcinoma. Following the validation of the BE-Smart™ test, which boasts an impressive technical success rate exceeding 95%, this patent solidifies ProPhase's commitment to early detection of esophageal diseases.
The Importance of BE-Smart™
The BE-Smart™ molecular diagnostic tool is pivotal in identifying risks associated with esophageal disorders. It has showcased exceptional versatility by effectively working with both brush and forceps biopsies. By leveraging these techniques, BE-Smart™ captures a wider range of epithelial cell types, making it a comprehensive tool for clinicians aiming to detect issues early and improve patient outcomes.
Understanding the Patent's Provisions
U.S. Patent No. 12379378-B2 was filed on December 7, 2023, by its inventors, Joe Abdo, Sumeet K. Mittal, and Devendra K. Agrawal. This patent encompasses methods that enable healthcare professionals to evaluate the risk of Barrett's esophagus and esophageal adenocarcinoma by detecting critical biomarkers such as ISG15, LTF, and others.
Scientific Significance of the Discoveries
The implications of this scientific breakthrough are far-reaching. The patented methods not only play a crucial role in risk analysis but also pave the way for novel treatment approaches. These may include methods for inhibiting cancer cell growth and enhancing the effectiveness of traditional therapies, ultimately aiding in better patient management.
ProPhase Labs' Vision for the Future
“This remarkable achievement, following the validation of BE-Smart™, reinforces our leadership in medical innovation. It brings us closer to transforming early detection and treatment strategies for esophageal conditions,” stated Ted Karkus, the Chief Executive Officer of ProPhase Labs. With the newly issued patent, the company aims to accelerate the commercialization of BE-Smart™, making it accessible to a broader range of patients and healthcare facilities.
Company Overview
ProPhase Labs, Inc. stands at the forefront of the biotechnology and diagnostics industries. Its mission is to create a healthier world through pioneering innovations. The company is known for its Whole Genome Sequencing solutions and the development of groundbreaking diagnostic tools like BE-Smart™, aimed at early cancer detection. With a direct-to-consumer model for health supplements, ProPhase is uniquely positioned for sustainable growth in the health tech sector.
Frequently Asked Questions
What is the significance of the newly issued patent for ProPhase Labs?
The patent protects ProPhase's innovative methods for assessing risks associated with esophageal diseases, enhancing early detection capabilities.
How does BE-Smart™ contribute to cancer diagnosis?
BE-Smart™ demonstrates high technical success in detecting biomarkers from various biopsy techniques, improving early diagnostic accuracy.
What are the key biomarkers identified in the patent?
The patent covers biomarkers such as ISG15, LTF, CNDP2, and others crucial for assessing Barrett's esophagus and cancer risk.
Who are the inventors of the patented technology?
The patent was developed by Joe Abdo, Sumeet K. Mittal, and Devendra K. Agrawal, showcasing expertise in the field.
What is ProPhase's long-term vision?
ProPhase Labs aims to enhance healthcare through innovative solutions and broaden access to their diagnostic tools, shaping future medical practices.
